argenx (NASDAQ:ARGX – Get Free Report) had its price target dropped by research analysts at Truist Financial from $570.00 to $550.00 in a research note issued on Wednesday, Benzinga reports. The firm currently has a “buy” rating on the stock. Truist Financial’s price objective suggests a potential upside of 24.84% from the company’s current price. […]
argenx (NASDAQ:ARGX – Get Free Report) and Outlook Therapeutics (NASDAQ:OTLK – Get Free Report) are both medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their risk, earnings, valuation, institutional ownership, analyst recommendations, dividends and profitability. Earnings and Valuation This table compares argenx and Outlook […]
Shares of argenx SE (NASDAQ:ARGX – Get Free Report) have received an average recommendation of “Moderate Buy” from the nineteen research firms that are currently covering the company, MarketBeat.com reports. One equities research analyst has rated the stock with a sell recommendation, two have given a hold recommendation and sixteen have issued a buy recommendation […]
Shares of argenx SE (NASDAQ:ARGX – Get Free Report) have been assigned an average recommendation of “Moderate Buy” from the nineteen brokerages that are covering the firm, Marketbeat Ratings reports. One analyst has rated the stock with a sell recommendation, two have issued a hold recommendation and sixteen have assigned a buy recommendation to the […]
Sei Investments Co. reduced its holdings in shares of argenx SE (NASDAQ:ARGX – Free Report) by 2.5% during the second quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 260,158 shares of the company’s stock after selling 6,716 shares during the period. Sei Investments Co. owned about […]